Women With Mucinous, Tubular/Cribriform Breast Cancer Fare Better Than Other Histotypes

Share this content:
Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes.
Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes.

Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes in the monotherapy cohort of the BIG 1-98 trial, according to an article printed online ahead of print in the Annals of Oncology.1

Investigators studied the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort (5 years with tamoxifen or letrozole) of the BIG 1-98 trial.

The cohort included 4,922 women, of whom 4,091 had central pathology review. Histotype groups were defined as mucinous (n=100), tubular/cribriform (n=83), ductal (n=3,257), and other (n=651). Of the 183 women with mucinous, tubular/cribriform tumors, 96 were randomly assigned to receive letrozole and 87 to tamoxifen.

At a median follow-up of 8.1 years, patients with tubular/cribriform breast cancer had the best outcomes in disease-free survival, overall survival, breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI) compared with all other histotypes.

Results showed that those with the tubular/cribriform histotype had a 5-year BCFI of 97.5% compared with 93.5% (mucinous), 88.9% (ductal), or 89.9% (other). Five-year DRFI rates were 97.8% in those with tubular histotype and 98.8% in cribriform, 90.9% in ductal, and 92.1% in other.

“Within the subgroup of women with special histotypes, we observed a non-significant increase in the hazard of breast cancer recurrence with letrozole (HR [letrozole vs tamoxifen]: 3.31, 95% CI: 0.94-11.7; P=0.06),” the authors wrote.

RELATED: First-Line Fulvestrant May Prolong Survival in Advanced Breast Cancer

Although women with the mucinous or tubular/cribriform histotypes of breast cancer had a better outcome in this study, the observation was based on a limited number of events, authors cautioned. The magnitude of the letrozole advantage may not be as large in patients with mucinous or tubular/cribriform disease in this patient population.

Reference

  1. Munzone E, Giobbie-Hurder A, Gusterson BA, et al. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. [published online ahead of print September 19, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv391.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters